Effect of attenuation correction on lesion detectability in FDG PET of breast cancer

Journal of Nuclear Medicine

Volumn 40, Issue 12, 1999, Pages 2021-2024

  Bleckmann, Christian ^a   Dose, Jörg ^a   Bohuslavizki, Karl H ^a   Buchert, Ralph ^a   Klutmann, Susanne ^a   Mester, Janos ^a   Jänicke, Fritz ^a   Clausen, Malte ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Attenuation correction; Breast cancer; Lesion detection; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ATTENUATION;

AXILLA; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; LYMPHATIC METASTASIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033371872     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Wingo PA, Ries LAG, Rosenberg HM, Miller DS. Edwards BK. Cancer incidence and mortality: 1973-1995. Cancer. 1998;82:1197-1207.
2. Chu KC, Smart CR, Tarone RB. Analysis of breast cancer mortality and stage distribution by age for the health insurance plan trial. J Natl Cancer Inst. 1988;80:1125-1132.
3. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
4. Kopans DB, Meyer JE, Sadowsky N. Breast imaging. N Engl J Med. 1984;310: 960-967.
5. Heywang SH, Wolf A, Pruss E, et al. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology. 1989;171:95-103.
6. Egan RL, Egan KL. Detection of breast carcinoma: comparison of automated water-path whole-breast sonography, mammography, and physical examination. AJR. 1984;143:493-497.
7. Hermann G, Janus C, Schwartz IS, et al. Nonpalpable breast lesions: accuracy of prebiopsy mammographic diagnosis. Radiology. 1987;165:323-326.
8. Jackson VP. The role of ultrasound in breast imaging. Radiology. 1990;177:305-311.
9. Kacl GM, Liu P, Debatin JF, Garzoli E, Caduff RF, Krestin GP. Detection of breast cancer with conventional mammography and contrast-enhanced MR imaging. Eur Radiol. 1998;8:194-200.
10. Kubota K, Matsuzwana T, Amemiya A, et al. Imaging of breast cancer with (18-F) fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr. 1989;13:1097-1098.
11. Minn H, Soini I. (18-F) fluorodeoxyglucose scintigraphy in the diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15:61-66.
12. Avril N, Dose J, Jänicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst. 1996;88:1204-1209.
13. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431-435.
14. 18F]-D-glucose. Cancer. 1998;82:2227-2234.
15. Jansson T, Westlin JE, Ahlström H, Lilja B, Langström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol. 1995;13:1470-1477.
16. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med. 1996;37: 931-938.
17. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
18. Noh DY, Yun IJ, Kim JS, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg. 1998;22:223-227.
19. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med. 1998; 39:4-8.
20. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer. 1993;71:3920-3925.
21. Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med. 1997;38:1186-1191
22. Avril N, Dose J, Jänicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18-fluorodeoxyglucose. J Clin Oncol. 1996;14:1848-1857.
23. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-R-glucose PET. Radiology. 1993;187:743-750.
24. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastases: screening with [F-18] 2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology. 1997;203:323-327.
25. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorode-oxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Ear J Nucl Med. 1996;23:1588-1593.
26. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991;179:765-770.
27. Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Ear J Nucl Med. 1997;24: 1091-1098.
28. Minn H, Leskinen-Kallio S, Lindholm P, et al. (18-F) fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr. 1993;17:115-123
29. Wienhard K, Eriksson L, Grootoonk S, Casey ME, Pietrzyk U, Heiss WD. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr. 1992;16:804-813.
30. Carroll LR, Kretz P, Orcutt G. The orbiting rod source: improving performance in PET transmission correction scans. In: Esser PD, ed. Emission Computed Tomography: Current Trends. New York, NY: Society of Nuclear Medicine; 1983:235-247.
31. Carson RE, Daube-Witherspoon ME, Green MV. A method for postinjection PET transmission measurements with a rotating source. J Nucl Med. 1988;29:1558-1567.
32. Schulz G, Ostwald E, Schreckenberger M, et al. Attenuation corrected myocardial PET using post injection transmission measurement: influence on relative regional uptake values. Nuklearmedizin. 1998;37:166-170.
33. Ostertag H, Kübler WK, Doll J, Lorenz W. Measured attenuation correction methods. Eur J Nucl Med. 1989;15:722-726.
34. Zasadny K, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847-850.
35. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601-609.
36. Meikle SR, Hutton BF, Baily DL, Hooper PK, Fulham MJ. Accelerated EM reconstruction in total body PET: potential for improving tumour detectability. Phys Med Biol. 1994;39:1689-1704.
37. Bleckmann C, Buchert R, Schulte U. et al. Onco-PET: lesion detection by computer display versus standardized documentation on film. Nukleurmedizin. 1999;38:56-60.
38. Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med. 1998;42:1-7.
39. 18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung. Ear J Nucl Med. 1996;23:517-523.
40. Huang SC, Hoffman EJ, Phelps ME, Kuhl DE. Quantification in positron emission computed tomography: effects of inaccurate attenuation correction. J Comput Assist Tomogr. 1979;3:804-814.